IQVIA Holdings Inc (IQV)vsMorgan Stanley (MS)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
MS
Morgan Stanley
$165.65
-0.13%
FINANCIAL SERVICES · Cap: $263.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Morgan Stanley generates 331% more annual revenue ($70.30B vs $16.31B). MS leads profitability with a 24.0% profit margin vs 8.3%. IQV appears more attractively valued with a PEG of 0.97. MS earns a higher WallStSmart Score of 76/100 (B+).
IQV
Strong Buy72
out of 100
Grade: B
MS
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Margin of Safety
+59.3%
Fair Value
$407.18
Current Price
$165.65
$241.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Keeps 24 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 20.7% YoY
Areas to Watch
Distress zone — elevated risk
Expensive relative to growth rate
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : MS
The strongest argument for MS centers on Market Cap, Operating Margin, Profit Margin. Profitability is solid with margins at 24.0% and operating margin at 38.6%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : MS
The primary concerns for MS are PEG Ratio, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
IQV profiles as a value stock while MS is a mature play — different risk/reward profiles.
IQV carries more volatility with a beta of 1.41 — expect wider price swings.
MS is growing revenue faster at 11.0% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
MS scores higher overall (76/100 vs 72/100), backed by strong 24.0% margins and 11.0% revenue growth. IQV offers better value entry with a 49.1% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Morgan Stanley
FINANCIAL SERVICES · CAPITAL MARKETS · USA
Morgan Stanley is an American multinational investment bank and financial services company headquartered at 1585 Broadway in the Morgan Stanley Building, Midtown Manhattan, New York City.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?